Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
|Articles|May 6, 2013
Aging eyes deserve evidence-based reporting, research
"Look for evidence, and don't fall for iffy claims," says Liz Seegert in Associations of Health Care Journalists blog.
Advertisement
“Aging eyes deserve reporting based on science and best practices,” writes Liz Seegert, topic leader on aging for the Association of Health Care Journalists (AHCJ).
Writing in a blog on the AHCJ Web site, Seegert urges journalists to “look for clinical evidence and not fall for unsupported or iffy claims.” Seegert directs her colleagues to a concise directive on what journalists need to know to evaluate research. [http://healthjournalism.org/core-topic.php?id=4]
Seegert’s blog sets a good example by including:
Advertisement
Related to this article
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
3
More than monitoring: Using AMD visits to promote healthy vision aging
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5